Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730270 | 0.91 | SHMT2 (0.36) | DRD4MAPTMAPK1DRD2HTR2A | |
| SCHEMBL6727663 | 0.88 | DRD4 (0.37) | DRD4MAPTMAPK1DRD2HTR2A | |
| SCHEMBL6726494 | 0.74 | SHMT2 (0.33) | DRD4MAPTMAPK1SHMT2 | |
| SCHEMBL3039668 | 0.72 | MAOA (0.40) | DRD4MAPTMAPK1DRD2HTR2A | |
| SCHEMBL6726488 | 0.71 | DRD4 (0.34) | DRD4MAPTMAPK1DRD2HTR2A | |
| SCHEMBL6728469 | 0.70 | TUBB4A (0.32) | MAPK1TP53 | |
| SCHEMBL6272423 | 0.69 | MAOA (0.50) | — | |
| SCHEMBL3042152 | 0.66 | MAOA (0.51) | DRD4MAPTMAPK1DRD2HTR2A | |
| SCHEMBL3045776 | 0.66 | MAOA (0.40) | DRD4MAPTMAPK1SHMT2KDM4E | |
| SCHEMBL6730272 | 0.66 | P2RX7 (0.33) | DRD4MAPTMAPK1DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | DRD4 1295/4885MAPT 4491/4885MAPK1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.